logo
Plus   Neg
Share
Email

Kopin In Asset Purchase Agreement With Solos Technology - Quick Facts

Kopin Corp. (KOPN), a developer of wearable computing technologies and solutions, announced Monday that it has entered into an Asset Purchase Agreement with Solos Technology Ltd.

The Purchase Agreement will see Kopin selling and licensing to Solos certain assets of its Solos product line and Whisper Audio technology. On August 8, 2019 Kopin announced its intention to spin out these assets to a group of employees and investors.

As consideration for the transaction, Kopin received 1.17 million common shares representing a 20.0 percent equity stake in the buyer's parent company, Solos Inc.

Kopin's 20.0 percent equity stake will be maintained until Solos Inc. has raised a total of $7.5 million in equity financing.

Kopin will also receive a royalty in the single digits on the net sales amount of Solos products for a four-year period, after commencement of commercial production. Kopin's Hong Kong employees have been offered employment with the Buyer and most are expected to transition to the new company.

Additionally, Kopin has a non-exclusive, limited, fully paid-up, royalty-free worldwide license, including modification of or improvement or enhancement to the Whisper technology, for enterprise and military customers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
RELATED NEWS
Follow RTT